Cialis Interactions with Other Drugs

See Eli Lilly and Company v.

• Cialis is a medication used to treat erectile dysfunction.
• Cialis contains the active ingredient tadalafil.
• It is available by prescription at pharmacies.
• Cialis helps improve blood flow to the penis.
• The usual dose is 10mg or 20mg before activity.
• Cialis can be taken with or without food.
• The effects of Cialis last up to 36 hours.
• Common side effects include headache and flushing.
• Cialis is not suitable for everyone; consult a doctor first.
• It may interact with nitrates and other medications.
• Cialis can be purchased online with a valid prescription.
• Always follow the dosage instructions given by your pharmacist.

media/broadcasting, Lee Shung, D2010-1079 (WIPO, September 14, 2010) (determining that the respondent did not have any right or legitimate interest in the domain <36cialis.com> where the respondent sold unauthorized or counterfeit products of the complainant).� Respondents clearly chose the Domain Names in order to create an impression of association with Complainant and Complainant's well-known CIALIS mark.� In light of these factors, it is apparent from the websites associated with the Domain Names that the Respondents are attempting to capitalize on the valuable reputation and goodwill of the CIALIS mark to direct Internet users to its websites.�� � ���(2)� Respondents are not authorized by Complainant to use the CIALIS trademark. Complainant has not given Respondents permission, authorization, consent or license to use its CIALIS mark.� Despite this fact, however, the Domain Names resolve to websites enabling the Respondents to benefit from the strength of Complainant's CIALIS mark and the reputation and goodwill of the product with which the mark is associated. [c.]��������� The Domain Names were registered and are being used in bad faith.

What is Cialis used for?

"� See Healthy Back LLC v. Ivo Somoza, D2003-0276 (WIPO, June 3, 2003).� Respondents' registration and misleading use of the Domain Names is disrupting to Complainant's business.� Finally, Respondents� use of Complainant's CIALIS mark in the Domain Names is potentially harmful to the health of many unsuspecting consumers who may purchase unlawfully sold pharmaceutical products promoted through the websites associated with the Domain Names under the mistaken impression that they are dealing with Complainant and, therefore, are receiving information on safe and effective drugs approved by the FDA or other health authorities around the world.� As discussed above, �Generic� CIALIS brand product has neither been developed by the Complainant nor approved by the FDA or any other health authority.� Complainant's CIALIS brand cialis online canada no prescription product is only available on a physician's prescription and is manufactured, labeled, and sold in strict compliance with the FDA and other health authority laws and regulations.� A prior panel has noted that the obvious danger of consumers being afforded inaccurate, incomplete or misleading information about medical products may further demonstrate a Respondent's bad faith.� See Eli Lilly and Company v. Ryma Nynyore/Domain Directors Pty. Ltd., D2011-0478 (WIPO, April 29, 2011).� In light of all of these factors, it is apparent that the Respondents have clearly registered and are using the Domain Names in bad faith.� Respondent failed to submit a Response in this proceeding. (1) the domain names registered by Respondent are identical or confusingly similar to a trademark or service mark in which Complainant has rights; and (2) Respondent has no rights or legitimate interests in respect of the domain names; and (3) the domain names were registered and are being used in bad faith.

User Reviews

Paragraph 15(a) of the Rules instructs this Panel to "decide a complaint on the basis of the statements and documents submitted in accordance with the Policy, these Rules and any rules and principles of law that it deems applicable." Paragraph 4(a) of the Policy requires Complainant prove the following three elements to obtain an order cancelling or transferring a domain name: (1) the domain name registered by Respondent is identical or confusingly similar to a trademark or service mark in which Complainant has rights; and (2) Respondent has no rights or legitimate interests in respect of the domain name; and (3) the domain name has been registered and is being used in bad faith. In view of Respondent's failure to submit a response, the Panel shall decide this administrative proceeding on the basis of Complainant's undisputed representations pursuant to paragraphs 5(f), 14(a) and 15(a) of the Rules and draw such inferences it considers appropriate pursuant to paragraph 14(b) of the Rules.� The Panel is entitled to accept all reasonable allegations and inferences set forth in the Complaint as true unless the evidence is clearly contradictory.� See Vertical Solutions Mgmt., Inc. v. webnet-marketing, inc., FA 95095 (Nat. Forum July 31, 2000) (holding that the respondent�s failure to respond allows all reasonable inferences of fact in the allegations of the complaint to be deemed true); see also Talk City, Inc. Complainant has a June 17, 1999 constructive use date of the CIALIS trademark based upon its U.S.

trademark rights.� Media coverage of the CIALIS brand product is dated as early as 2001.� Complainant has extensively marketed and advertised its pharmaceutical product using the CIALIS trademark.� Therefore, because it is reasonable to infer that the CIALIS trademark is well-known, it is highly likely that the Respondents knew of Complainant's CIALIS mark at the time of registering over 70 confusingly similar Domain Names. According to Policy �4(b)(ii), evidence of bad faith registration and use is shown when a respondent has registered a domain name in order to prevent the trademark owner from reflecting the mark in a corresponding domain name, provided the respondent has engaged in a pattern of such conduct.�� See Eli Lilly and Company v. Darren K.

Headley et al., D2103-1303 (WIPO, September 4, 2013) (registering 10 domain names incorporating the CIALIS mark demonstrated that the respondent registered and was using the disputed domain names in bad faith per paragraph 4(b)(ii)).� Moreover, prior Forum Panels found that the registration of multiple domains incorporating the Complainant�s CIALIS mark revealed bad faith registration and use pursuant to Policy �4(b)(ii).� See Eli Lilly and Company v. Igor Palchikov, FA 1105001388612 (NAF, June 15, 2011) (Annex 3, P) and Eli Lilly and Company v. Grace Beaumont et. al, FA1504001615093 (NAF, June 5, 2015).� In this case, the Respondents have registered over 70 domains which incorporate the Complainant's CIALIS mark.

Patient Forms

v. Robertson, D2000-0009 (WIPO Feb. 29, 2000) (�In the absence of a response, it is appropriate to accept as true all allegations of the Complaint.�). Complainant has requested these proceedings be consolidated.� For the purposes of clarity and to insure the Panel�s ruling is understandable to readers who are not parties, Complaint�s request will be set out in full:� Complainant hereby requests permission to proceed against multiple respondents in this single administrative proceeding pursuant to �3(c) or 10(e) of the UDRP Rules.� The consolidation of multiple registrants as respondents in a single administrative proceeding is appropriate under �3(c) or 10(e) of the UDRP Rules provided the complainant can demonstrate that the disputed domain names or the websites to which they resolve are subject to common control, and the Panel, having regard to all of the relevant circumstances, determines that consolidation would be procedurally efficient and fair and equitable to all parties. Moreover, in order to establish a pattern of conduct, one need not demonstrate an impact against multiple trademark owners.� Instead, while a pattern of conduct typically involves multiple domain names directed against multiple complainants, it may involve multiple domain names directed against a single complainant.� See Telstra Corporation Limited v.

Ozurls, D2001-0046 (WIPO, March 20, 2001) (finding that fifteen domain names that involved Telstra's mark and a series of services, products, geographical descriptors, or generic words obviously involves a pattern of conduct directed against Telstra, stopping it from reflecting its mark in corresponding domain names).� Such is the case here, where the Respondents registered over 70 Domain Names, all of which incorporate the Complainant's well-known and distinctive CIALIS mark.� Further, promoting competing products under another�s mark disrupts a trademark owner�s business and reveals bad faith registration and use according to Policy �4(b)(iii). See Eli Lilly and Company v. Igor Palchikov, FA 1105001388612 (NAF, June 15, 2011).� In this case, several of the websites associated with the Domain Names promote illegal, counterfeit pharmaceutical products, as well as competing products which demonstrates bad faith use and registration pursuant to the Policy. Additionally, the Respondents are likely using Complainant's CIALIS mark in the Domain Names to drive Internet traffic to its websites and likely profiting from the purchase of any products from the associated online pharmacy.� Prior NAF Panels have noted that such activities create a likelihood of confusion as to the source, sponsorship or affiliation of the resolving websites, from which a respondent presumably profits and demonstrates bad faith registration and use according to Policy �4(b)(iv). See Eli Lilly and Company v.

Office Hours

Igor Palchikov, FA 1105001388612 (NAF, June 15, 2011).� In this case, several of the websites associated with the Domain Names promote illegal, counterfeit pharmaceutical products, as well as competing products which demonstrates bad faith use and registration pursuant to the Policy. Additionally, the Respondents are likely using Complainant's CIALIS mark in the Domain Names to drive Internet traffic to its websites and likely profiting from the purchase of any products from the associated online pharmacy.� Prior NAF Panels have noted that such activities create a likelihood of confusion as to the source, sponsorship or affiliation of the resolving websites, from which a respondent presumably profits and demonstrates bad faith registration and use according to Policy �4(b)(iv). See Eli Lilly and Company v. Igor Palchikov, FA 1105001388612 (NAF, June 15, 2011) (Annex 3, P).� Moreover, prior NAF Panels have found, �that the offer of counterfeit and competing products constitutes bad faith attraction for commercial gain under Policy �4(b)(iv).�� See Eli Lilly and Company v. Grace Beaumont et.

Special Precautions

One may argue that the Respondents� conduct with respect to 10 of the Domain Names that currently don�t have active websites cannot be said to come squarely within any of the examples of bad faith registration and use set out in �4(b) of the Policy. However, the examples in �4(b) are intended to be illustrative, rather than exclusive. See Telstra Corporation Limited v. Nuclear Marshmallows, D2000-0003 (WIPO, February 18, 2000) (Annex 3, R). As discussed in detail above, the Telstra decision established that "inaction" can constitute bad faith use, and the decision has since been cited for that proposition and followed by many subsequent Panels.

Doctor Preferences

See Staples, Inc. v. Ryan Conrad, D2003-0713 (WIPO, October 27, 2003) (Annex 3, V). As a result, Respondents' passive and misleading use of 10 of the Domain Names constitutes bad faith registration and use. "It is further important to state that the mere holding of a domain name that is identical or confusingly similar to a trademark belonging to someone else, prevents the holder of the said mark to be present on the Internet under a domain name that reflects the trademark, which in itself can be considered disrupting to his business. Igor Palchikov, FA 1105001388612 (NAF, June 15, 2011) (Annex 3, P).� Moreover, prior NAF Panels have found, �that the offer of counterfeit and competing products constitutes bad faith attraction for commercial gain under Policy �4(b)(iv).�� See Eli Lilly and Company v. Grace Beaumont et. One may argue that the Respondents� conduct with respect to 10 of the Domain Names that currently don�t have active websites cannot be said to come squarely within any of the examples of bad faith registration and use set out in �4(b) of the Policy. However, the examples in �4(b) are intended to be illustrative, rather than exclusive.

What Dosages and Forms is Cialis available in?

See Eli Lilly and Company v. media/broadcasting, Lee Shung, D2010-1079 (WIPO, September 14, 2010) (determining that the respondent did not have any right or legitimate interest in the domain <36cialis.com> where the respondent sold unauthorized or counterfeit products of the complainant).� Respondents clearly chose the Domain Names in order to create an impression of association with Complainant and Complainant's well-known CIALIS mark.� In light of these factors, it is apparent from the websites associated with the Domain Names that the Respondents are attempting to capitalize on the valuable reputation and goodwill of the CIALIS mark to direct Internet users to its websites.�� � ���(2)� Respondents are not authorized by Complainant to use the CIALIS trademark. Complainant has not given Respondents permission, authorization, consent or license to use its CIALIS mark.� Despite this fact, however, the Domain Names resolve to websites enabling the Respondents to benefit from the strength of Complainant's CIALIS mark and the reputation and goodwill of the product with which the mark is associated. [c.]��������� The Domain Names were registered and are being used in bad faith. Complainant has a June 17, 1999 constructive use date of the CIALIS trademark based upon its U.S.

Payment Methods

trademark rights.� Media coverage of the CIALIS brand product is dated as early as 2001.� Complainant has extensively marketed and advertised its pharmaceutical product using the CIALIS trademark.� Therefore, because it is reasonable to infer that the CIALIS trademark is well-known, it is highly likely that the Respondents knew of Complainant's CIALIS mark at the time of registering over 70 confusingly similar Domain Names. According to Policy �4(b)(ii), evidence of bad faith registration and use is shown when a respondent has registered a domain name in order to prevent the trademark owner from reflecting the mark in a corresponding domain name, provided the respondent has engaged in a pattern of such conduct.�� See Eli Lilly and Company v. Darren K. Headley et al., D2103-1303 (WIPO, September 4, 2013) (registering 10 domain names incorporating the CIALIS mark demonstrated that the respondent registered and was using the disputed domain names in bad faith per paragraph 4(b)(ii)).� Moreover, prior Forum Panels found that the registration of multiple domains incorporating the Complainant�s CIALIS mark revealed bad faith registration and use pursuant to Policy �4(b)(ii).� See Eli Lilly and Company v. Igor Palchikov, FA 1105001388612 (NAF, June 15, 2011) (Annex 3, P) and Eli Lilly and Company v.

Pharmacy Availability

Grace Beaumont et. al, FA1504001615093 (NAF, June 5, 2015).� In this case, the Respondents have registered over 70 domains which incorporate the Complainant's CIALIS mark. Moreover, in order to establish a pattern of conduct, one need not demonstrate an impact against multiple trademark owners.� Instead, while a pattern of conduct typically involves multiple domain names directed against multiple complainants, it may involve multiple domain names directed against a single complainant.� See Telstra Corporation Limited v. Ozurls, D2001-0046 (WIPO, March 20, 2001) (finding that fifteen domain names that involved Telstra's mark and a series of services, products, geographical descriptors, or generic words obviously involves a pattern of conduct directed against Telstra, stopping it from reflecting its mark in corresponding domain names).� Such is the case here, where the Respondents registered over 70 Domain Names, all of which incorporate the Complainant's well-known and distinctive CIALIS mark.� Further, promoting competing products under another�s mark disrupts a trademark owner�s business and reveals bad faith registration and use according to Policy �4(b)(iii). See Eli Lilly and Company v. See Telstra Corporation Limited v. Nuclear Marshmallows, D2000-0003 (WIPO, February 18, 2000) (Annex 3, R). As discussed in detail above, the Telstra decision established that "inaction" can constitute bad faith use, and the decision has since been cited for that proposition and followed by many subsequent Panels. See Staples, Inc. v. Ryan Conrad, D2003-0713 (WIPO, October 27, 2003) (Annex 3, V). As a result, Respondents' passive and misleading use of 10 of the Domain Names constitutes bad faith registration and use. "It is further important to state that the mere holding of a domain name that is identical or confusingly similar to a trademark belonging to someone else, prevents the holder of the said mark to be present on the Internet under a domain name that reflects the trademark, which in itself can be considered disrupting to his business.

• The future of ED treatment may include new formulations like rapidly dissolving tablets or creams.
• Research is ongoing into stem cell therapy and gene therapy as potential long-term solutions.
• The field of telemedicine is expected to continue growing, improving access to ED consultations.
• Artificial intelligence may eventually be used to help personalize treatment plans based on big data.
• Despite advances, the foundation of treatment will remain a combination of lifestyle changes and medicine.
• Patient education is paramount for the safe and effective use of any medication, including Cialis.
• Understanding how the drug works, its benefits, and its risks empowers you to be an active participant.
• Reliable sources of information include your doctor, pharmacist, and official health organization websites.
• Be skeptical of sensationalized claims or "miracle cures" advertised online or elsewhere.
• A trusted healthcare team is your best resource for managing your health and treatment successfully.

"� See Healthy Back LLC v. Ivo Somoza, D2003-0276 (WIPO, June 3, 2003).� Respondents' registration and misleading use of the Domain Names is disrupting to Complainant's business.� Finally, Respondents� use of Complainant's CIALIS mark in the Domain Names is potentially harmful to the health of many unsuspecting consumers who may purchase unlawfully sold pharmaceutical products promoted through the websites associated with the Domain Names under the mistaken impression that they are dealing with Complainant and, therefore, are receiving information on safe and effective drugs approved by the FDA or other health authorities around the world.� As discussed above, �Generic� CIALIS brand product has neither been developed by the Complainant nor approved by the FDA or any other health authority.� Complainant's CIALIS brand cialis online canada no prescription product is only available on a physician's prescription and is manufactured, labeled, and sold in strict compliance with the FDA and other health authority laws and regulations.� A prior panel has noted that the obvious danger of consumers being afforded inaccurate, incomplete or misleading information about medical products may further demonstrate a Respondent's bad faith.� See Eli Lilly and Company v. Ryma Nynyore/Domain Directors Pty. Ltd., D2011-0478 (WIPO, April 29, 2011).� In light of all of these factors, it is apparent that the Respondents have clearly registered and are using the Domain Names in bad faith.� Respondent failed to submit a Response in this proceeding.

• Purchase Cialis only from licensed pharmacies.
• Verify the medication’s packaging for authenticity.
• Beware of counterfeit Cialis sold online.
• Store Cialis in a cool, dry place.
• Keep Cialis out of reach of children.
• Do not use Cialis if you have heart issues.
• Discuss your medical history before use.
• Report any adverse reactions to your doctor.
• Cialis is contraindicated with certain medications.
• Do not exceed the prescribed dosage.
• Be aware of possible side effects like dizziness.
• Consult your doctor for proper usage guidance.

(1) the domain names registered by Respondent are identical or confusingly similar to a trademark or service mark in which Complainant has rights; and (2) Respondent has no rights or legitimate interests in respect of the domain names; and (3) the domain names were registered and are being used in bad faith. Paragraph 15(a) of the Rules instructs this Panel to "decide a complaint on the basis of the statements and documents submitted in accordance with the Policy, these Rules and any rules and principles of law that it deems applicable." Paragraph 4(a) of the Policy requires Complainant prove the following three elements to obtain an order cancelling or transferring a domain name: (1) the domain name registered by Respondent is identical or confusingly similar to a trademark or service mark in which Complainant has rights; and (2) Respondent has no rights or legitimate interests in respect of the domain name; and (3) the domain name has been registered and is being used in bad faith. In view of Respondent's failure to submit a response, the Panel shall decide this administrative proceeding on the basis of Complainant's undisputed representations pursuant to paragraphs 5(f), 14(a) and 15(a) of the Rules and draw such inferences it considers appropriate pursuant to paragraph 14(b) of the Rules.� The Panel is entitled to accept all reasonable allegations and inferences set forth in the Complaint as true unless the evidence is clearly contradictory.� See Vertical Solutions Mgmt., Inc. v. webnet-marketing, inc., FA 95095 (Nat. Forum July 31, 2000) (holding that the respondent�s failure to respond allows all reasonable inferences of fact in the allegations of the complaint to be deemed true); see also Talk City, Inc. v. Robertson, D2000-0009 (WIPO Feb.

• Adherence to the prescribed regimen is critical for achieving the best results with treatment.
• For daily dosing, taking the pill at the same time each day helps maintain steady drug levels.
• Setting a daily reminder or using a pill organizer can help prevent missed doses.
• Do not increase your dose without talking to your doctor, even if you feel the medication isn't working.
• It may take a few attempts or dosage adjustments to find what works best for you.
• Keeping a log of your responses can help your doctor fine-tune your treatment plan.
• Note the timing of the dose, presence of sexual stimulation, and the quality of the erection.
• Also record any side effects you experience and their severity.
• This data provides valuable objective information for your healthcare provider.
• Be patient; finding the right treatment approach is often a process of adjustment.

29, 2000) (�In the absence of a response, it is appropriate to accept as true all allegations of the Complaint.�). Complainant has requested these proceedings be consolidated.� For the purposes of clarity and to insure the Panel�s ruling is understandable to readers who are not parties, Complaint�s request will be set out in full:� Complainant hereby requests permission to proceed against multiple respondents in this single administrative proceeding pursuant to �3(c) or 10(e) of the UDRP Rules.� The consolidation of multiple registrants as respondents in a single administrative proceeding is appropriate under �3(c) or 10(e) of the UDRP Rules provided the complainant can demonstrate that the disputed domain names or the websites to which they resolve are subject to common control, and the Panel, having regard to all of the relevant circumstances, determines that consolidation would be procedurally efficient and fair and equitable to all parties.